Literature DB >> 25173886

PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.

Hong Pu1, Craig Horbinski2, Patrick J Hensley1, Emily A Matuszak3, Timothy Atkinson1, Natasha Kyprianou4.   

Abstract

Poly (ADP-ribose) polymerase (PARP) is involved in key cellular processes such as DNA replication and repair, gene transcription, cell proliferation and apoptosis. The role of PARP-1 in prostate cancer development and progression is not fully understood. The present study investigated the function of PARP-1 in prostate growth and tumorigenesis in vivo. Functional inactivation of PARP-1 by gene-targeted deletion led to a significant reduction in the prostate gland size in young PARP-1-/- mice (6 weeks) compared with wild-type (WT) littermates. To determine the effect of PARP-1 functional loss on prostate cancer onset, PARP-1-/- mice were crossed with the transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Pathological assessment of prostate tumors revealed that TRAMP+/-, PARP-1-/- mice exhibited higher grade prostate tumors compared with TRAMP+/- PARP-1+/+ (16-28 weeks) that was associated with a significantly increased proliferative index and decreased apoptosis among the epithelial cells in TRAMP+/- PARP-1-/- prostate tumors. Furthermore tumors harboring PARP-1 loss, exhibited a downregulation of nuclear androgen receptor. Impairing PARP-1 led to increased levels of transforming growth factor-β (TGF-β) and Smads that correlated with induction of epithelial-mesenchymal transition (EMT), as established by loss of E-cadherin and β-catenin and upregulation of N-cadherin and ZEB-1. Our findings suggest that impaired PARP-1 function promotes prostate tumorigenesis in vivo via TGF-β-induced EMT. Defining the EMT control by PARP-1 during prostate cancer progression is of translational significance for optimizing PARP-1 therapeutic targeting and predicting response in metastatic castration-resistant prostate cancer.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25173886      PMCID: PMC4216059          DOI: 10.1093/carcin/bgu183

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  50 in total

Review 1.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

2.  Complete reversal of epithelial to mesenchymal transition requires inhibition of both ZEB expression and the Rho pathway.

Authors:  Shreyas Das; Bryan N Becker; F Michael Hoffmann; Janet E Mertz
Journal:  BMC Cell Biol       Date:  2009-12-21       Impact factor: 4.241

3.  Poly(ADP-ribose)-dependent regulation of Snail1 protein stability.

Authors:  M I Rodríguez; A González-Flores; F Dantzer; J Collard; A G de Herreros; F J Oliver
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

4.  Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.

Authors:  Yiwei Lin; Tiebang Kang; Binhua P Zhou
Journal:  Cell Cycle       Date:  2014-03-25       Impact factor: 4.534

5.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

6.  Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.

Authors:  Hong Pu; Joanne Collazo; Elisabeth Jones; Dustin Gayheart; Shinichi Sakamoto; Adam Vogt; Bonnie Mitchell; Natasha Kyprianou
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

7.  Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.

Authors:  Younghun Jung; Jin Koo Kim; Yusuke Shiozawa; Jingcheng Wang; Anjali Mishra; Jeena Joseph; Janice E Berry; Samantha McGee; Eunsohl Lee; Hongli Sun; Jianhua Wang; Taocong Jin; Honglai Zhang; Jinlu Dai; Paul H Krebsbach; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.

Authors:  Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles
Journal:  Br J Cancer       Date:  2011-09-27       Impact factor: 7.640

9.  Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

Authors:  S K Sandhu; A Omlin; L Hylands; S Miranda; L J Barber; R Riisnaes; A H Reid; G Attard; L Chen; I Kozarewa; H Gevensleben; J Campbell; K Fenwick; I Assiotis; D Olmos; T A Yap; P Fong; N Tunariu; D Koh; L R Molife; S Kaye; C J Lord; A Ashworth; J de Bono
Journal:  Ann Oncol       Date:  2013-03-22       Impact factor: 32.976

10.  Resistance to PARP-Inhibitors in Cancer Therapy.

Authors:  Alicia Montoni; Mihaela Robu; Emilie Pouliot; Girish M Shah
Journal:  Front Pharmacol       Date:  2013-02-27       Impact factor: 5.810

View more
  28 in total

Review 1.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 2.  PARP Inhibitors in Prostate Cancer.

Authors:  Praveen Ramakrishnan Geethakumari; Matthew J Schiewer; Karen E Knudsen; Wm Kevin Kelly
Journal:  Curr Treat Options Oncol       Date:  2017-06

Review 3.  Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.

Authors:  Zheng Cao; Theodore Livas; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2016

4.  Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.

Authors:  Bin Gui; Fu Gui; Tomoaki Takai; Chao Feng; Xiao Bai; Ladan Fazli; Xuesen Dong; Shuai Liu; Xiaofeng Zhang; Wei Zhang; Adam S Kibel; Li Jia
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-02       Impact factor: 11.205

5.  Immunohistochemical Evaluation of PARP and Caspase-3 as Prognostic Markers in Prostate Carcinomas.

Authors:  Vitoria Acar; Fabio Leite Couto Fernandez; Fabio Fabian Buscariolo; Adriana Alonso Novais; Roseli Aparecida Matheus Pereira; Debora Aparecida Pires de Campos Zuccari
Journal:  Clin Med Res       Date:  2021-12

6.  Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.

Authors:  Lydia Livas; Sumati Hasani; Natasha Kyprianou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 7.  Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors.

Authors:  José Yélamos; Miguel Galindo; Judith Navarro; Joan Albanell; Ana Rovira; Federico Rojo; Javier Oliver
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

Review 8.  The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.

Authors:  Máté A Demény; László Virág
Journal:  Cancers (Basel)       Date:  2021-04-24       Impact factor: 6.639

9.  Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy.

Authors:  Patrick J Hensley; Natasha Kyprianou; Matthew S Purdom; Daheng He; Vincent DiCarlo; Chi Wang; Andrew C James
Journal:  Urol Oncol       Date:  2019-07-17       Impact factor: 2.954

10.  PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Authors:  Germano Mariano; Maria Rosaria Ricciardi; Daniela Trisciuoglio; Michele Zampieri; Fabio Ciccarone; Tiziana Guastafierro; Roberta Calabrese; Elisabetta Valentini; Agostino Tafuri; Donatella Del Bufalo; Paola Caiafa; Anna Reale
Journal:  Oncotarget       Date:  2015-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.